Menu
GeneBe

BAAT

bile acid-CoA:amino acid N-acyltransferase

Basic information

Region (hg38): 9:101354181-101385400

Links

ENSG00000136881NCBI:570OMIM:602938HGNC:932Uniprot:Q14032AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hypercholanemia, familial 1 (Strong), mode of inheritance: AR
  • familial hypercholanemia (Limited), mode of inheritance: Unknown
  • familial hypercholanemia (Supportive), mode of inheritance: AR
  • bile acid CoA:amino acid N-acyltransferase deficiency (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Hypercholanemia, familial; Bile acid conjugation defect 1ARGastrointestinal; HematologicIndividuals with Hypercholanemia may present with manifestations including pruritus, sequelae of fat malabsorption (which can be severe), and elevated serum bile acid concentrations, which typically respond to medical treatment (eg, with ursodeoxycholic acid and fat-soluble vitamins); Individuals with Bile acid conjugation defect , which can include janudice, failure to thrive, rickets, growth deficiency, and coagulopathy, have been reported as responding to medical management (eg, with ursodeoxycholic acid, FFP and vitamin K); Liver transplant has been describedGastrointestinal; Hematologic12704386; 22783059; 23415802

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the BAAT gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the BAAT gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
8
clinvar
11
clinvar
1
clinvar
20
missense
46
clinvar
5
clinvar
4
clinvar
55
nonsense
3
clinvar
3
start loss
1
clinvar
1
frameshift
2
clinvar
2
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
1
1
non coding
38
clinvar
7
clinvar
19
clinvar
64
Total 0 0 98 23 24

Variants in BAAT

This is a list of pathogenic ClinVar variants found in the BAAT region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
9-101360430-A-G Hypercholanemia, familial 1 Benign (Jan 13, 2018)364246
9-101360538-G-T Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)364247
9-101360542-A-G Hypercholanemia, familial 1 Benign (Jan 13, 2018)364248
9-101360544-C-T Hypercholanemia, familial 1 Benign (Jan 13, 2018)364249
9-101360564-C-A Hypercholanemia, familial 1 Uncertain significance (Jan 12, 2018)912310
9-101360600-G-A Hypercholanemia, familial 1 Uncertain significance (Jan 12, 2018)912311
9-101360604-G-A Hypercholanemia, familial 1 Likely benign (Jan 13, 2018)364250
9-101360716-C-G Hypercholanemia, familial 1 Uncertain significance (Jan 15, 2018)912312
9-101360727-C-G Hypercholanemia, familial 1 Likely benign (Jan 13, 2018)364251
9-101360811-G-A Hypercholanemia, familial 1 Likely benign (Jan 13, 2018)913430
9-101360831-G-T Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)913431
9-101360853-A-C Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)364252
9-101360871-G-T Hypercholanemia, familial 1 Uncertain significance (Jan 12, 2018)913432
9-101360900-G-T Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)913433
9-101360953-C-T Hypercholanemia, familial 1 Benign (Jan 13, 2018)364253
9-101360970-C-T Hypercholanemia, familial 1 Benign (Jan 13, 2018)364254
9-101361006-T-C Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)913434
9-101361087-T-C Hypercholanemia, familial 1 Uncertain significance (Jan 12, 2018)913811
9-101361112-T-G Hypercholanemia, familial Uncertain significance (Jun 14, 2016)364255
9-101361121-A-T Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)913812
9-101361210-T-C Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)364256
9-101361222-TG-T Hypercholanemia, familial Uncertain significance (Jun 14, 2016)364257
9-101361251-CTA-C Hypercholanemia, familial Likely benign (Jun 14, 2016)364258
9-101361264-G-A Hypercholanemia, familial Uncertain significance (Jun 14, 2016)364259
9-101361289-A-C Hypercholanemia, familial 1 Uncertain significance (Jan 13, 2018)364260

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
BAATprotein_codingprotein_codingENST00000259407 323103
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
7.87e-80.2921256930441257370.000175
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.01342212220.9970.00001152696
Missense in Polyphen5775.6420.75355965
Synonymous-0.5469285.61.080.00000446868
Loss of Function0.5001214.00.8568.23e-7162

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004460.000446
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.0001500.000149
Middle Eastern0.0001090.000109
South Asian0.0003270.000327
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: Involved in bile acid metabolism. In liver hepatocytes catalyzes the second step in the conjugation of C24 bile acids (choloneates) to glycine and taurine before excretion into bile canaliculi. The major components of bile are cholic acid and chenodeoxycholic acid. In a first step the bile acids are converted to an acyl-CoA thioester, either in peroxisomes (primary bile acids deriving from the cholesterol pathway), or cytoplasmic at the endoplasmic reticulum (secondary bile acids). May catalyze the conjugation of primary or secondary bile acids, or both. The conjugation increases the detergent properties of bile acids in the intestine, which facilitates lipid and fat-soluble vitamin absorption. In turn, bile acids are deconjugated by bacteria in the intestine and are recycled back to the liver for reconjugation (secondary bile acids). May also act as an acyl-CoA thioesterase that regulates intracellular levels of free fatty acids. In vitro, catalyzes the hydrolysis of long- and very long-chain saturated acyl-CoAs to the free fatty acid and coenzyme A (CoASH), and conjugates glycine to these acyl-CoAs. {ECO:0000269|PubMed:12810727, ECO:0000269|PubMed:8034703}.;
Pathway
Bile secretion - Homo sapiens (human);Peroxisome - Homo sapiens (human);Biosynthesis of unsaturated fatty acids - Homo sapiens (human);Taurine and hypotaurine metabolism - Homo sapiens (human);Primary bile acid biosynthesis - Homo sapiens (human);27-Hydroxylase Deficiency;Bile Acid Biosynthesis;Congenital Bile Acid Synthesis Defect Type II;Cerebrotendinous Xanthomatosis (CTX);Zellweger Syndrome;Familial Hypercholanemia (FHCA);Congenital Bile Acid Synthesis Defect Type III;Drug Induction of Bile Acid Pathway;Farnesoid X Receptor Pathway;Nuclear Receptors Meta-Pathway;One carbon metabolism and related pathways;Metapathway biotransformation Phase I and II;metabolism of anandamide an endogenous cannabinoid;Metabolism of lipids;Metabolism of proteins;Tyrosine metabolism;Leukotriene metabolism;Saturated fatty acids beta-oxidation;Metabolism;Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol;Methionine Cysteine metabolism;Synthesis of bile acids and bile salts;Recycling of bile acids and salts;Bile acid and bile salt metabolism;Peroxisomal protein import;Metabolism of steroids;Bile acid biosynthesis;De novo fatty acid biosynthesis;Vitamin E metabolism;bile acid biosynthesis, neutral pathway (Consensus)

Recessive Scores

pRec
0.106

Intolerance Scores

loftool
0.846
rvis_EVS
0.71
rvis_percentile_EVS
85.63

Haploinsufficiency Scores

pHI
0.0447
hipred
N
hipred_score
0.123
ghis

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
gene_indispensability_pred
N
gene_indispensability_score
0.256

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Baat
Phenotype

Gene ontology

Biological process
liver development;bile acid conjugation;glycine metabolic process;protein targeting to peroxisome;fatty acid metabolic process;acyl-CoA metabolic process;bile acid biosynthetic process;bile acid metabolic process;taurine metabolic process;animal organ regeneration
Cellular component
peroxisome;peroxisomal matrix;cytosol
Molecular function
signaling receptor binding;protein binding;palmitoyl-CoA hydrolase activity;N-acyltransferase activity;transferase activity, transferring acyl groups;acyl-CoA hydrolase activity;glycine N-choloyltransferase activity;carboxylic ester hydrolase activity;medium-chain acyl-CoA hydrolase activity;long-chain acyl-CoA hydrolase activity;very long chain acyl-CoA hydrolase activity;myristoyl-CoA hydrolase activity